The Trade and Cooperation Agreement (TCA) between the UK and the EU was finalized on December 24, 2020, nearly five years after the Brexit referendum of 2016. Even though the TCA guarantees tariff-free trade between both sides, industries will face additional barriers as the EU and the UK will now function as separate legal and regulatory jurisdictions. While the UK’s separation from the EU presents an opportunity for UK’s life-science sector to grow and establish the UK as an innovative regulator, Brexit will continue to generate uncertainty about the prospects of research, manufacturing, funding, regulatory affairs, and trade in the pharmaceutical industry.
In this report, the publisher examines the business environment, weighs the opportunities, and assesses the risks that the UK’s pharmaceutical industry is going to face post Brexit. The report also highlights the COVID-19 impact on the UK’s economy as major macro events, such as Brexit and the ongoing COVID-19 pandemic, are continuing to affect the UK’s pharmaceutical industry in parallel.
Scope
The research source in this report is based on the opinions and expectations of 150 global healthcare industry professionals surveyed from February 8, 2021, to March 3, 2021 to gauge Brexit impact on the healthcare industry. Components of the report include -
Reasons to Buy
In this report, the publisher examines the business environment, weighs the opportunities, and assesses the risks that the UK’s pharmaceutical industry is going to face post Brexit. The report also highlights the COVID-19 impact on the UK’s economy as major macro events, such as Brexit and the ongoing COVID-19 pandemic, are continuing to affect the UK’s pharmaceutical industry in parallel.
Scope
The research source in this report is based on the opinions and expectations of 150 global healthcare industry professionals surveyed from February 8, 2021, to March 3, 2021 to gauge Brexit impact on the healthcare industry. Components of the report include -
- Outcomes of Brexit: best outcomes of Brexit providing respondent mix by geography as compared to previous survey waves in 2018 and 2019
- Impact on Research and Manufacturing: key factors to impact healthcare research and manufacturing in the UK post-Brexit providing respondent mix by region as compared to previous survey waves in 2018 and 2019
- Factors to Impact Healthcare: key factors to impact the post-Brexit UK healthcare industry providing respondent mix by region as compared to previous survey waves in 2018 and 2019
- Impact on Corporate Strategy: level of impact of Brexit on corporate strategy providing respondent mix by region as compared to previous survey waves in 2018 and 2019
- COVID-19 Impact: COVID-19 impact on the UK’s economy as major macro events, such as Brexit and the ongoing COVID-19 pandemic, are continuing to affect the UK’s pharmaceutical industry in parallel
- Future Prospects: overview of the initiatives that could help the UK’s healthcare sector to recover and emerge strong post-Brexit
Reasons to Buy
- Develop and design your corporate strategies post-Brexit through an in-house expert analysis of the key factors to impact the post-Brexit UK healthcare industry.
- Develop business strategies by understanding the key factors to impact healthcare research and manufacturing in the UK post-Brexit.
- Stay up to date on the industry’s changing sentiment towards Brexit from within the healthcare industry.
- Identify emerging industry trends post-Brexit to gain a competitive advantage.
Table of Contents
1. Study Design
2. Executive Summary
3. UK Pharma Industry and Brexit
4. Outcome of Brexit
5. Impact on Research and Manufacturing
6. Factors to Impact Healthcare
7. Impact on Corporate Strategy
8. Impact on Corporate Strategy
9. Future Prospects